Development Level

Tbio 17 | 11,445
Tclin 7 | 613
Tchem 2 | 1,598

IMPC Phenotype

increased circulating triglyce... 2 | 42
abnormal embryo size 1 | 220
decreased circulating glucose ... 1 | 126
decreased large unstained cell... 1 | 11
decreased leukocyte cell numbe... 1 | 73
decreased neutrophil cell numb... 1 | 42
hemorrhage 1 | 23
increased circulating sodium l... 1 | 71
increased hematocrit 1 | 46
increased leukocyte cell numbe... 1 | 47
preweaning lethality, complete... 1 | 979
preweaning lethality, incomple... 1 | 499
tremors 1 | 39
unresponsive to tactile stimul... 1 | 8

Disease

Carcinoma 26 | 11,493
osteosarcoma 19 | 7,950
glioblastoma 16 | 5,792
Cancer 14 | 2,499
lung carcinoma 14 | 2,843
non-small cell lung cancer 13 | 2,890
interstitial cystitis 12 | 2,312
ovarian cancer 12 | 8,520
lung cancer 11 | 4,740
tuberculosis 11 | 2,010
Astrocytoma, Pilocytic 10 | 3,081
malignant mesothelioma 10 | 3,232
Autosomal recessive predisposition 9 | 1,442
Breast cancer 9 | 3,578
Kidney cancer 9 | 2,613
invasive ductal carcinoma 9 | 2,951
medulloblastoma, large-cell 9 | 6,241
pancreatic cancer 9 | 2,398
psoriasis 9 | 6,694
adult high grade glioma 8 | 3,801
ulcerative colitis 8 | 1,819
Gliosis 7 | 56
cystic fibrosis 7 | 1,696
ependymoma 7 | 4,679
lung adenocarcinoma 7 | 2,716
Liver Cirrhosis, Experimental 6 | 769
atypical teratoid / rhabdoid tumor 6 | 5,112
cutaneous lupus erythematosus 6 | 1,057
diabetes mellitus 6 | 1,728
Duchenne muscular dystrophy 5 | 601
Leukocyte adhesion deficiency 5 | 16
Multiple Sclerosis 5 | 540
colon cancer 5 | 1,478
group 3 medulloblastoma 5 | 4,104
intraductal papillary-mucinous adenoma (IPMA) 5 | 2,955
intraductal papillary-mucinous carcinoma (IPMC) 5 | 2,989
intraductal papillary-mucinous neoplasm (IPMN) 5 | 3,291
primary pancreatic ductal adenocarcinoma 5 | 1,109
Acute Promyelocytic Leukemia 4 | 40
Anemia 4 | 365
Arthritis 4 | 290
Crohn's disease 4 | 321
Leukemia, Promyelocytic, Acute 4 | 36
Prenatal onset 4 | 139
Schizophrenia 4 | 1,160
Vascular disease 4 | 319
astrocytoma 4 | 1,146
dermatomyositis 4 | 966
ductal carcinoma in situ 4 | 1,745
head and neck cancer 4 | 271
pediatric high grade glioma 4 | 1,064
subependymal giant cell astrocytoma 4 | 2,287
Asthma 3 | 385
Autoimmune thrombocytopenic purpura 3 | 13
Cerebral Hemorrhage 3 | 42
Cerebrovascular accident 3 | 63
Cerebrovascular disease 3 | 238
Colon carcinoma in situ 3 | 9
Coronary artery disease 3 | 268
Defective enamel matrix 3 | 35
Dental Enamel Hypoplasia 3 | 43
Dermatitis 3 | 157
Down syndrome 3 | 499
Dysplasia of tooth enamel 3 | 35
Ecchymosis 3 | 66
Endometriosis 3 | 540
Epidermolysis bullosa 3 | 21
FNAITP 3 | 6
Fragile skin 3 | 18
Glanzmann's thrombasthenia 3 | 23
Hemoglobin low 3 | 124
Hypersensitivity reaction type II disease 3 | 253
Increased tendency to bruise 3 | 66
Inflammatory Bowel Diseases 3 | 35
Inflammatory bowel disease 3 | 151
Leukopenia 3 | 72
Purpura 3 | 43
RENAL ADYSPLASIA 3 | 25
Renal dysplasia 3 | 28
Stroke 3 | 33
Thin dental enamel 3 | 35
Thrombocytopenia 3 | 197
breast carcinoma 3 | 1,638
gastric carcinoma 3 | 807
group 4 medulloblastoma 3 | 1,855
mucosa-associated lymphoid tissue lymphoma 3 | 484
oligodendroglioma 3 | 2,850
pancreatic carcinoma 3 | 562
pancreatic ductal adenocarcinoma liver metastasis 3 | 1,962
primary Sjogren syndrome 3 | 735
primitive neuroectodermal tumor 3 | 3,035
Abdomen distended 2 | 43
Arthrogryposis 2 | 54
Autistic Disorder 2 | 364
Influenza 2 | 142
Polyhydramnios 2 | 108
Proteinuria 2 | 144
Systemic lupus erythematosus 2 | 194
hereditary spastic paraplegia 2 | 318
posterior fossa group A ependymoma 2 | 468

Tissue

Blood and immune system 26 | 16,909
Cardiovascular System 26 | 15,192
Digestive Tract 26 | 17,369
Endocrine System 26 | 18,159
Female tissues 26 | 17,400
Liver and Pancreas 26 | 16,750
Male tissues 26 | 17,142
Respiratory system 26 | 16,393
Skin and soft tissues 26 | 17,230
Urinary Tract 26 | 16,678
Nervous System 25 | 16,725

Target Family

Non-IDG 26 | 12,091

PathwayCommons: pid Pathway

http://pathwaycommons.org/pc2/... 26 | 26
http://pathwaycommons.org/pc2/... 137 | 137
http://pathwaycommons.org/pc2/... 125 | 125
http://pathwaycommons.org/pc2/... 102 | 102
http://pathwaycommons.org/pc2/... 87 | 87
http://pathwaycommons.org/pc2/... 87 | 87
http://pathwaycommons.org/pc2/... 85 | 85
http://pathwaycommons.org/pc2/... 82 | 82
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 77 | 77
http://pathwaycommons.org/pc2/... 74 | 74
http://pathwaycommons.org/pc2/... 74 | 74
http://pathwaycommons.org/pc2/... 71 | 71
http://pathwaycommons.org/pc2/... 71 | 71
http://pathwaycommons.org/pc2/... 70 | 70
http://pathwaycommons.org/pc2/... 70 | 70
http://pathwaycommons.org/pc2/... 69 | 69
http://pathwaycommons.org/pc2/... 67 | 67
http://pathwaycommons.org/pc2/... 67 | 67
http://pathwaycommons.org/pc2/... 67 | 67
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 65 | 65
http://pathwaycommons.org/pc2/... 65 | 65
http://pathwaycommons.org/pc2/... 65 | 65
http://pathwaycommons.org/pc2/... 64 | 64
http://pathwaycommons.org/pc2/... 64 | 64
http://pathwaycommons.org/pc2/... 63 | 63
http://pathwaycommons.org/pc2/... 63 | 63
http://pathwaycommons.org/pc2/... 63 | 63
http://pathwaycommons.org/pc2/... 62 | 62
http://pathwaycommons.org/pc2/... 61 | 61
http://pathwaycommons.org/pc2/... 60 | 60
http://pathwaycommons.org/pc2/... 59 | 59
http://pathwaycommons.org/pc2/... 59 | 59
http://pathwaycommons.org/pc2/... 58 | 58
http://pathwaycommons.org/pc2/... 57 | 57
http://pathwaycommons.org/pc2/... 56 | 56
http://pathwaycommons.org/pc2/... 56 | 56
http://pathwaycommons.org/pc2/... 55 | 55
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 53 | 53
http://pathwaycommons.org/pc2/... 53 | 53
http://pathwaycommons.org/pc2/... 53 | 53
http://pathwaycommons.org/pc2/... 51 | 51
http://pathwaycommons.org/pc2/... 50 | 50
http://pathwaycommons.org/pc2/... 50 | 50
http://pathwaycommons.org/pc2/... 50 | 50
http://pathwaycommons.org/pc2/... 49 | 49
http://pathwaycommons.org/pc2/... 49 | 49
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 47 | 47
http://pathwaycommons.org/pc2/... 47 | 47
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 45 | 45
http://pathwaycommons.org/pc2/... 45 | 45
http://pathwaycommons.org/pc2/... 44 | 44
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 41 | 41
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 39 | 39
http://pathwaycommons.org/pc2/... 39 | 39
http://pathwaycommons.org/pc2/... 39 | 39
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 37 | 37
http://pathwaycommons.org/pc2/... 37 | 37
http://pathwaycommons.org/pc2/... 37 | 37
http://pathwaycommons.org/pc2/... 36 | 36

This is where graphics are reside..
Name Gene Development Level Target Family Log Novelty  Pubmed Score  Antibody Count  Knowledge Availability 
Integrin alpha-11 ITGA11 Tbio Non-IDG -1.13736 14.3 76
Integrin alpha-7 ITGA7 Tbio Non-IDG -1.63563 42.4 193
Integrin alpha-M ITGAM Tbio Non-IDG -3.63427 3939.5 2165
Integrin alpha-E ITGAE Tbio Non-IDG -2.61450 414.3 758
Integrin alpha-8 ITGA8 Tbio Non-IDG -1.36974 22.0 145
Integrin alpha-L ITGAL Tclin Non-IDG -2.90090 757.3 1407
Integrin alpha-X ITGAX Tbio Non-IDG -3.23986 1600.6 1515
Integrin alpha-4 ITGA4 Tclin Non-IDG -2.53262 310.4 1312
Integrin alpha-10 ITGA10 Tbio Non-IDG -0.86801 7.54 15
Integrin alpha-5 ITGA5 Tbio Non-IDG -2.29130 169.1 826